Published in J Immunol on December 01, 1974
Mycobacterium. Bacteriol Rev (1977) 3.20
The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol (2009) 2.87
Concanavalin A-activated suppressor cells in normal human peripheral blood lymphocytes. Clin Exp Immunol (1976) 1.61
Dengue virus-induced thymus-derived suppressor cells in the spleen of mice. Immunology (1979) 1.50
Regulatory B cells in autoimmune diseases. Cell Mol Immunol (2013) 1.36
Immunocompetent cells in resistance to bacterial infections. Bacteriol Rev (1976) 1.31
The relation of immune depression and B-cell stimulation during the development of delayed hypersensitivity to soluble antigens. Immunology (1977) 1.23
Thymus-dependent lymphocytes of dengue virus-infected mice spleens mediate suppression through prostaglandin. Immunology (1981) 1.10
Distinction between suppressors of the delayed-type hypersensitivity and the humoral response to sheep erythrocytes. Immunology (1978) 1.09
Regulatory B cells and tolerance in transplantation: from animal models to human. Front Immunol (2013) 1.04
Acquired resistance to ticks. II. Effects of Cyclophosphamide on resistance. Immunology (1976) 1.03
Adjuvants in the induction of suppressor cells. Infect Immun (1979) 0.99
Effect of an acidic polysaccharide produced by Serratia piscatorum on immune responses im mice II. Stimulatory effects in normal and immunologically impaired animals. Immunology (1977) 0.90
Cyclophosphamide-induced eosinophilia in the rat: concomitant changes in T-cell subsets, B cells and large granular lymphocytes within lymphoid tissues. Immunology (1987) 0.87
Evidence for suppressor cell activity associated with induction of Herpesvirus saimiri-induced lymphoma. Clin Exp Immunol (1975) 0.85
Involvement of suppressive B-lymphocytes in the mechanism of tolerogenic dendritic cell reversal of type 1 diabetes in NOD mice. PLoS One (2014) 0.81
Augmentation of immune responses after methotrexate administration. Immunology (1979) 0.81
In vivo studies on the cellular source of migration inhibitory factor in mice with delayed hypersensitivity. Infect Immun (1977) 0.79
The role of pregnancy-associated hormones in the development and function of regulatory B cells. Front Endocrinol (Lausanne) (2014) 0.78
B-cell-mediated strategies to fight chronic allograft rejection. Front Immunol (2013) 0.77
Effect of anti-mu-chain-specific immunosuppression on Chikungunya virus encephalitis of mice. Infect Immun (1977) 0.76
Regulatory B Cells in Pregnancy: Lessons from Autoimmunity, Graft Tolerance, and Cancer. Front Immunol (2017) 0.75
Tolerance in Kidney Transplantation: What Is on the B Side? Mediators Inflamm (2016) 0.75
Modulation of the immune system in the mouse. 2. Drug administration following antigen sensitization. Agents Actions (1980) 0.75
B cell regulation in cancer and anti-tumor immunity. Cell Mol Immunol (2017) 0.75
Production and properties of migration inhibitory factor and interferon in the circulation of mice with delayed hypersensitivity. J Immunol (1973) 3.88
Communications. "In vitro" cell reactions in delayed hypersensitivity. J Immunol (1969) 2.03
Interleukin 1 is a radioprotector. J Immunol (1986) 1.80
Induction of colony stimulating factor in vivo by recombinant interleukin 1 alpha and recombinant tumor necrosis factor alpha 1. J Immunol (1987) 1.50
Recombinant interleukin-1 alpha and recombinant tumor necrosis factor alpha synergize in vivo to induce early endotoxin tolerance and associated hematopoietic changes. Infect Immun (1988) 1.48
Activity in vitro of lymphocytes and macrophages in delayed hypersensitivity. J Immunol (1971) 1.48
Migration inhibitory factor and type II interferon in the circulation of mice sensitized with mycobacterial components. J Immunol (1975) 1.33
Interaction of recombinant IL-1 and recombinant tumor necrosis factor in the induction of mouse acute phase proteins. J Immunol (1988) 1.25
Lymphoid cells in delayed hypersensitivity. 1. In vitro vs. in vivo responses. Cell Immunol (1970) 1.23
Roles of interleukin-1 and tumor necrosis factor in lipopolysaccharide-induced hypoglycemia. Infect Immun (1991) 1.23
T and B lymphocytes in the regulation of delayed hypersensitivity. J Immunol (1976) 1.18
Effect of liposome-mediated macrophage depletion on LPS-induced cytokine gene expression and radioprotection. J Immunol (1995) 1.18
Resistance and susceptibility to infection in inbred murine strains. I. Variations in the response to thymic hormones in mice infected with Candida albicans. Cell Immunol (1983) 1.16
Antibodies chaperone circulating IL-6. Paradoxical effects of anti-IL-6 "neutralizing" antibodies in vivo. J Immunol (1993) 1.15
Thymosin alpha 11: a peptide related to thymosin alpha 1 isolated from calf thymosin fraction 5. Proc Natl Acad Sci U S A (1983) 1.14
Immunologic unresponsiveness, immunity and enhancement in experimental allergic encephalomyelitis. J Immunol (1968) 1.14
In vivo release of lymphokines in different strains of mice. Cell Immunol (1980) 1.12
Interleukin-1 and interleukin-6 act synergistically to stimulate the release of adrenocorticotropic hormone in vivo. Lymphokine Cytokine Res (1991) 1.09
Synergistic roles of interleukin-6, interleukin-1, and tumor necrosis factor in the adrenocorticotropin response to bacterial lipopolysaccharide in vivo. Endocrinology (1993) 1.09
The role of interleukin-6 in lipopolysaccharide-induced weight loss, hypoglycemia and fibrinogen production, in vivo. Cytokine (1993) 1.08
Delayed hypersensitivity to cryptococcin in man. Sabouraudia (1968) 1.05
A possible relationship between delayed hypersensitivity and cell-mediated immunity. Am Rev Respir Dis (1975) 1.05
Lymphoid cells in delayed hypersensitivity. 3. The influence of x-irradiation on passive transfer and on in vitro production of soluble mediators. J Exp Med (1972) 1.05
Specific depression of delayed hypersensitivity to purified proteins, with relation to production of circulating antibody. Cell Immunol (1973) 1.04
An interleukin-1 receptor antagonist blocks lipopolysaccharide-induced colony-stimulating factor production and early endotoxin tolerance. Infect Immun (1991) 1.03
Tumor suppression by a lymphokine released into the circulation of mice with delayed hypersensitivity. J Natl Cancer Inst (1975) 1.01
Adjuvants in the induction of suppressor cells. Infect Immun (1979) 0.99
The in vivo effects of interleukin 1. I. Bone marrow cells are induced to cycle after administration of interleukin 1. J Immunol (1987) 0.98
Cellular source of interferons in the circulation of mice with delayed hypersensitivity. Infect Immun (1977) 0.96
Cellular immunity in vitro: migration inhibition and phagocytosis. Infect Immun (1971) 0.96
Resistance and susceptibility to infection in inbred murine strains. II. Variations in the effect of treatment with thymosin fraction 5 on the release of lymphokines in vivo. Cell Immunol (1983) 0.94
Interleukin-1 enhances survival of lethally irradiated mice treated with allogeneic bone marrow cells. Blood (1989) 0.92
Parathymosin alpha: a peptide from rat tissues with structural homology to prothymosin alpha. Proc Natl Acad Sci U S A (1985) 0.90
Human prothymosin alpha: amino acid sequence and immunologic properties. Arch Biochem Biophys (1986) 0.90
Mechanisms in the in vivo release of lymphokines: relationship of high and low responsiveness to other parameters of the immune response. Infect Immun (1981) 0.90
Immunologic unresponsiveness to allergic thyroiditis in guinea pigs. J Immunol (1967) 0.89
Tumor necrosis factor/cachectin is a less potent inducer of serum amyloid A synthesis than interleukin 1. Lymphokine Res (1987) 0.89
Type I and II interferons and migration inhibitory factor: production in Mycobacterium bovis BCG-infected mice desensitized with old tuberculin or lipopolysaccharide. Infect Immun (1978) 0.88
Pathophysiological roles of cytokines in development, immunity, and inflammation. FASEB J (1994) 0.87
Hematopoietic growth factors and glucocorticoids synergize to mimic the effects of IL-1 on granulocyte differentiation and IL-1 receptor induction on bone marrow cells in vivo. Exp Hematol (1993) 0.87
Constituents of the cell wall of the yeast phase of Histoplasma capsulatum. Am Rev Respir Dis (1965) 0.86
Mechanisms in the in vivo release of lymphokines. V. Responses in alloxan-treated and genetically diabetic mice. Cell Immunol (1981) 0.86
Two new inhibitory activities in blood of mice with delayed hypersensitivity, after challenge with specific antigen. Infect Immun (1974) 0.86
Cytokines in radioprotection. Comparison of the radioprotective effects of IL-1 to IL-2, GM-CSF and IFN gamma. Lymphokine Res (1986) 0.85
Increased fibrinogen synthesis in mice during the acute phase response: co-operative interaction of interleukin 1, interleukin 6, and interleukin 1 receptor antagonist. Cytokine (1993) 0.84
Effect of reserpine on immune reactions and tumour growth. Eur J Cancer (1966) 0.84
Mechanisms in the in vivo release of lymphokines. II. Regulation of in vivo release of type II interferon IFN gamma. Cell Immunol (1981) 0.84
Advances in radioprotection through the use of combined agent regimens. Int J Radiat Biol (1990) 0.84
Evaluation of immunologic assays to determine the effects of differential housing on immune reactivity. Brain Behav Immun (1990) 0.83
The effect of cyclophosphamide on suppressor cells in guinea pigs. Cell Immunol (1977) 0.83
Further studies on the mechanism of experimental autoimmune thyroiditis in guinea pigs. Properties of thyroid cytotoxic factor (TCF) and its relationship to pathogenesis of the disease. Cell Immunol (1976) 0.83
In vitro and in vivo studies on the mechanism of experimental autoimmune thyroiditis in guinea pigs. Cell Immunol (1976) 0.82
Effect of differential housing and time on immune reactivity to sheep erythrocytes and Candida. Brain Behav Immun (1987) 0.82
Mechanisms in the in vivo release of lymphokines. 1. Comparative kinetics in the release of six lymphokines in inbred strains of mice. Cell Immunol (1981) 0.81
An overview on interleukin-1 as a therapeutic agent. Biotherapy (1989) 0.81
Mechanisms in the in vivo release of lymphokines. VI. Studies with mice congenic at the H-2 region. Transplantation (1982) 0.80
Hypersensitivity to peptide fragments. Int Arch Allergy Appl Immunol (1967) 0.80
Recovery of hematopoietic colony-forming cells in irradiated mice pretreated with interleukin 1 (IL-1). Exp Hematol (1988) 0.79
Relationship between interleukin 1 (IL1), tumor necrosis factor (TNF) and a neutrophil attracting peptide (NAP-1). Agents Actions (1989) 0.79
In vivo studies on the cellular source of migration inhibitory factor in mice with delayed hypersensitivity. Infect Immun (1977) 0.79
Radioprotection of mice with interleukin-1: relationship to the number of spleen colony-forming units. Radiat Res (1989) 0.78
Aspects of cytokine induced modulation of immunity and inflammation with emphasis on interleukin 1. Arzneimittelforschung (1988) 0.78
Production of migration inhibitory factor in inbred rats. Int Arch Allergy Appl Immunol (1976) 0.77
Decreased vasopressin content in parvocellular CRH neurosecretory system of Lewis rats. Neuroreport (1994) 0.77
The effect of dietary zinc and prothymosin alpha on cellular immune responses of RF/J mice. Clin Immunol Immunopathol (1987) 0.76
Enhanced hematopoietic recovery in irradiated mice pretreated with interleukin-1 (IL-1). Immunopharmacol Immunotoxicol (1987) 0.76
Radioprotection of mice with interleukin-1: relationship to the number of erythroid and granulocyte-macrophage colony-forming cells. Radiat Res (1990) 0.75
Developing additional resources. Radiat Environ Biophys (2002) 0.75
Radioprotection with cytokines: a clarification of terminology. Cancer Cells (1991) 0.75
Resistance and susceptibility to infection in inbred murine strains. III. Effect of thymosin on cellular immune responses of alloxan diabetic mice. Clin Exp Immunol (1984) 0.75
IL2 release in atomic bomb survivors. Radiat Res (2001) 0.75
Interferons and lymphokines. Tex Rep Biol Med (1983) 0.75
Systemically administered histamine H1 and H2 receptor antagonists do not block the ACTH response to bacterial lipopolysaccharide and interleukin-1. Neuroendocrinology (1994) 0.75
Observations on migration inhibition of sensitized peritoneal exudate cells as a function of time. Cell Immunol (1974) 0.75
Mechanisms in in vivo release of lymphokines. III. Separation of gamma-interferon (IFN gamma) from cytotoxicity in inbred strains of mice. J Interferon Res (1981) 0.75
Effects of interleukin-1 on the stress-responsive and -nonresponsive subtypes of corticotropin-releasing hormone neurosecretory axons. Endocrinology (1992) 0.75
In vivo release of lymphokines in inbred murine strains. Lymphokine Res (1982) 0.75
Thymic hormones in radiation-induced immunodeficiency. I. Induction of mature interleukin 1 responsive cell in the thymus by thymosin fraction 5. Cell Immunol (1985) 0.75
Whole-body irradiation transiently diminishes the adrenocorticotropin response to recombinant human interleukin-1 alpha. Radiat Res (1995) 0.75
Modification of radiation-induced gastrointestinal and hematopoietic injury in mice by combinations of agents: effects of indomethacin and caffeine. Adv Exp Med Biol (1997) 0.75
Resistance and susceptibility to infection in inbred murine strains. IV. Effects of dietary zinc. Cell Immunol (1984) 0.75
Specificity of immunologic unresponsiveness. Fed Proc (1990) 0.75
Discussion paper: a tumor-inhibiting lymphokine from tuberculous mice. Ann N Y Acad Sci (1976) 0.75